Actinogen Medical Advances Oral Enzyme Inhibitor for Potential Alzheimer's Disease Treatment

MT Newswires Live

Aug 06

Actinogen Medical (ASX:ACW) presented Xanamem, an oral enzyme inhibitor that lowers brain cortisol levels by blocking the 11β-HSD1 enzyme, at the Bioshares Biotech Summit in New Zealand, according to a Thursday filing with the Australian bourse.

The company is advancing Xanamem for the potential treatment of Alzheimer's disease by blocking excess stress hormone cortisol production in brain cells, the filing said.

The company anticipates top-line results from the fully enrolled phase 2b/3 XanaMIA pivotal trial in November, following independent Data Monitoring Committee recommendation in January that the trial continue unchanged, per the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2657457083"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657457083\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657457083?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 08:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657457083","market":"hk","top_or_hot":-1,"title":"Actinogen Medical Advances Oral Enzyme Inhibitor for Potential Alzheimer's Disease Treatment","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ACW.AU\">Actinogen Medical</a> (ASX:ACW) presented Xanamem, an oral enzyme inhibitor that lowers brain cortisol levels by blocking the 11β-HSD1 enzyme, at the Bioshares Biotech <a href=\"https://laohu8.com/S/SMMT\">Summit</a> in New Zealand, according to a Thursday filing with the Australian bourse.</p><p>The company is advancing Xanamem for the potential treatment of Alzheimer's disease by blocking excess stress hormone cortisol production in brain cells, the filing said.</p><p>The company anticipates top-line results from the fully enrolled phase 2b/3 XanaMIA pivotal trial in November, following independent Data Monitoring Committee recommendation in January that the trial continue unchanged, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinogen Medical Advances Oral Enzyme Inhibitor for Potential Alzheimer's Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinogen Medical Advances Oral Enzyme Inhibitor for Potential Alzheimer's Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-06 08:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ACW.AU\">Actinogen Medical</a> (ASX:ACW) presented Xanamem, an oral enzyme inhibitor that lowers brain cortisol levels by blocking the 11β-HSD1 enzyme, at the Bioshares Biotech <a href=\"https://laohu8.com/S/SMMT\">Summit</a> in New Zealand, according to a Thursday filing with the Australian bourse.</p><p>The company is advancing Xanamem for the potential treatment of Alzheimer's disease by blocking excess stress hormone cortisol production in brain cells, the filing said.</p><p>The company anticipates top-line results from the fully enrolled phase 2b/3 XanaMIA pivotal trial in November, following independent Data Monitoring Committee recommendation in January that the trial continue unchanged, per the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657457083","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657457083","pubTimestamp":1785976497,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Actinogen Medical  presented Xanamem, an oral enzyme inhibitor that lowers brain cortisol levels by blocking the 11β-HSD1 enzyme, at the Bioshares Biotech Summit in New Zealand, according to a Thursday filing with the Australian bourse.The company is advancing Xanamem for the potential treatment of Alzheimer's disease by blocking excess stress hormone cortisol production in brain cells, the filing said.The company anticipates top-line results from the fully enrolled phase 2b/3 XanaMIA pivotal trial in November, following independent Data Monitoring Committee recommendation in January that the trial continue unchanged, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","ACW.AU":"ACTINOGEN MEDICAL LTD","BK7508":"医药生物股"},"translate_title":"Actinogen Medical 开发用于潜在阿尔茨海默病治疗的口服酶抑制剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACW.AU":1},"content_text":"Actinogen Medical (ASX:ACW) presented Xanamem, an oral enzyme inhibitor that lowers brain cortisol levels by blocking the 11β-HSD1 enzyme, at the Bioshares Biotech Summit in New Zealand, according to a Thursday filing with the Australian bourse.The company is advancing Xanamem for the potential treatment of Alzheimer's disease by blocking excess stress hormone cortisol production in brain cells, the filing said.The company anticipates top-line results from the fully enrolled phase 2b/3 XanaMIA pivotal trial in November, following independent Data Monitoring Committee recommendation in January that the trial continue unchanged, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}